{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:02:41Z","timestamp":1784991761599,"version":"3.55.0"},"reference-count":18,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC) portends a poor prognosis. DNA pathway repair mutations in HNSCC are associated with higher tumor mutational burden rates and immune checkpoint inhibitor response. PARP inhibitors (PARPi) induce ssDNA breaks and are efficacious in cancers with DNA repair defects. Thus, we designed a single-arm, open-label, phase II clinical trial to evaluate the combination of niraparib and dostarlimab in patients with R\/M HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with R\/M HNSCC were treated with niraparib and dostarlimab until disease progression or unacceptable toxicity. The primary endpoint was the overall response rate and clinical benefit assessed by RECIST version 1.1. Using Simon\u2019s two-step minimax design, 14 patients were planned to enroll in the first stage with a goal of overall clinical benefit of 50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ten patients were enrolled. The majority were White males with a median age of 62.5. One patient had a PD-L1 combined positive score &amp;gt;20, a high tumor mutational burden, a BRCA1 rearrangement, and an ATRX splice site mutation. Nine patients previously failed anti\u2013PD-1\/PD-L1 therapy. The best overall response rate was 10%, with a 20% clinical benefit (1 partial response, 1 stable disease). The trial was terminated early for futility as the goal clinical benefit could not be reached. At a median follow-up of 10.13 months, the median progression-free survival was 3.8 months, and the median overall survival was 10.1 months. The most common grade 3 or higher treatment-related adverse events were thrombocytopenia and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The combination of niraparib and dostarlimab did not achieve the primary endpoint of clinical benefit, but activity may be improved with biomarker-driven treatment and selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Patients with R\/M HNSCC that progress on PD-1 inhibitors have poor prognoses. PARPis cause ssDNA breaks that accumulate in cells with mutations in DNA damage repair pathways, leading to synthetic lethality. However, PARPi also inhibits glycogen synthase kinase-3\u03b2 activity, leading to upregulated PD-L1, which is abrogated by PD-1 inhibitors. In this study, we combine niraparib (PARPi) with dostarlimab (anti\u2013PD-L1) to evaluate clinical benefit in patients with R\/M HNSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0192","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:44:12Z","timestamp":1747395852000},"page":"939-944","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5769-7425","authenticated-orcid":false,"given":"Olga","family":"Zamulko","sequence":"first","affiliation":[{"name":"1Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-8410","authenticated-orcid":false,"given":"Vidhya","family":"Karivedu","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Duke University Medical Center, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-7862","authenticated-orcid":false,"given":"Muhammad Kashif","family":"Riaz","sequence":"additional","affiliation":[{"name":"3St. Elizabeth Healthcare, Edgewood, Kentucky."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-7042","authenticated-orcid":false,"given":"Ilaina","family":"Monroe","sequence":"additional","affiliation":[{"name":"4University of Cincinnati Cancer Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2553-681X","authenticated-orcid":false,"given":"Audrey","family":"Romano","sequence":"additional","affiliation":[{"name":"4University of Cincinnati Cancer Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4722-032X","authenticated-orcid":false,"given":"Rachel","family":"Mulanda","sequence":"additional","affiliation":[{"name":"4University of Cincinnati Cancer Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4797-2571","authenticated-orcid":false,"given":"Nicky","family":"Kurtzweil","sequence":"additional","affiliation":[{"name":"4University of Cincinnati Cancer Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9802-3502","authenticated-orcid":false,"given":"Allie","family":"Forsythe","sequence":"additional","affiliation":[{"name":"4University of Cincinnati Cancer Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-5320","authenticated-orcid":false,"given":"Casey L.","family":"Allen","sequence":"additional","affiliation":[{"name":"4University of Cincinnati Cancer Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-3413","authenticated-orcid":false,"given":"Nusrat","family":"Harun","sequence":"additional","affiliation":[{"name":"5Cytel, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5998-3481","authenticated-orcid":false,"given":"Jianmin","family":"Pan","sequence":"additional","affiliation":[{"name":"6Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio."},{"name":"7Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio."},{"name":"8Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-353X","authenticated-orcid":false,"given":"Shesh","family":"Rai","sequence":"additional","affiliation":[{"name":"6Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio."},{"name":"7Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio."},{"name":"8Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-8283","authenticated-orcid":false,"given":"Dalia","family":"El-Gamal","sequence":"additional","affiliation":[{"name":"1Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-4028","authenticated-orcid":false,"given":"Trisha M.","family":"Wise-Draper","sequence":"additional","affiliation":[{"name":"1Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2025060905113180200_bib1","article-title":"An interactive website for SEER cancer statistics. Surveillance Research Program","author":"SEER Explorer"},{"key":"2025060905113180200_bib2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.32583","article-title":"Rising incidence of late-stage head and neck cancer in the United States","volume":"126","author":"Thompson-Harvey","year":"2020","journal-title":"Cancer"},{"key":"2025060905113180200_bib3","doi-asserted-by":"crossref","first-page":"109661","DOI":"10.1016\/j.biopha.2019.109661","article-title":"Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer","volume":"123","author":"Zheng","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2025060905113180200_bib4","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"2025060905113180200_bib5","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.3390\/cancers13133118","article-title":"Prevalence of DNA repair gene mutations in blood and tumor tissue and impact on prognosis and treatment in HNSCC","volume":"13","author":"Burcher","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025060905113180200_bib6","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res"},{"key":"2025060905113180200_bib7","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025060905113180200_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"key":"2025060905113180200_bib9","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"2025060905113180200_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.33885","article-title":"JASPER: phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer","volume":"128","author":"Ramalingam","year":"2022","journal-title":"Cancer"},{"key":"2025060905113180200_bib11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41467-023-37084-w","article-title":"Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma","volume":"14","author":"Madariaga","year":"2023","journal-title":"Nat Commun"},{"key":"2025060905113180200_bib12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025060905113180200_bib13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025060905113180200_bib14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/03610918.2011.560732","article-title":"Confidence intervals for survival probabilities: a comparison study","volume":"40","author":"Yuan","year":"2011","journal-title":"Commun Stat Simulation Comput"},{"key":"2025060905113180200_bib15","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/cncr.32190","article-title":"Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial","volume":"125","author":"Haddad","year":"2019","journal-title":"Cancer"},{"key":"2025060905113180200_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025060905113180200_bib17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2025060905113180200_bib18","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.ijrobp.2024.01.096","article-title":"Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): a single-arm, phase 2 trial","volume":"5","author":"Oppelt","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0192\/3606559\/crc-25-0192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/939\/3620676\/crc-25-0192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/939\/3620676\/crc-25-0192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:11:41Z","timestamp":1749445901000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/6\/939\/762896\/Phase-II-Study-Evaluating-the-Efficacy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0192","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29267161","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267173","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267170","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267143","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267155","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267164","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267158","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267167","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29267146","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7864774","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}